Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use of GLP-1 analogs in the treatment of multiple sclerosis
2019-003001-94Phase 2Active
- Sponsor
- Faculty of Medicine, Comenius University Bratislava
- Start
- Sep 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of dulaglutide in relapsing-remitting multiple sclerosis (RRMS) and insulin resistance (IR), sponsored by Faculty of Medicine, Comenius University Bratislava. Started Sep 2019; status: active.
02
Drugs
dulaglutide
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)insulin resistance (IR)
Beyond the preview
Go deeper on 2019-003001-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003001-94.